-
Product Insights
NewLikelihood of Approval Analysis for Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that the drugs in Recurrent Glioblastoma Multiforme (GBM) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recurrent Glioblastoma Multiforme (GBM) Overview Recurrent glioblastoma multiforme (GBM) refers...
-
Thematic Analysis
NewUkraine Conflict Impact – Thematic Intelligence
Ukraine Conflict Impact Report Overview The large-scale Russian invasion of Ukraine in February 2022 has dramatically restructured strategic priorities within the global defense sector either by developing innovative defense capabilities, or the re-invigorating previously stagnant market segments. As the geostrategic implications of this conflict continue to reverberate across global markets, the primary lesson learned is the need to upscale production capacity and leverage cost-efficiency across all domains of modern warfare, with investments driving innovation of both technology and operations throughout...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-024 in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in Systemic Mastocytosis Drug Details: MGD-024 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-024 in Hairy Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in Hairy Cell Leukemia Drug Details: MGD-024 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-3011 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-3011 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-3011 in Metastatic Colorectal Cancer Drug Details: T-3011 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-3011 in Malignant Ascites
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-3011 in Malignant Ascites report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-3011 in Malignant Ascites Drug Details: T-3011 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Sparsentan (Filspari)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-024 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-024 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in B-Cell Acute Lymphocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-3011 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-3011 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-3011 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
Goktepe RES, Turkey
Goktepe RES is located in Yalova, Turkey. The power plant was commissioned in 2022. Empower your strategies with our Goktepe RES report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough...